SEC Tracker
Get the app

Puma Biotechnology PBYI

Puma Biotechnology reports $55.06 million revenue for Q3 2026

Puma Biotechnology (PBYI) filed a 10-Q with the SEC on Nov 9, 2026, 4:33 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $55.06 million for the three months ended Sep 30, 2026
  2. Net income: $5.96 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $41.55 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Puma Biotechnology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

2 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange QoQ
Revenue$55.06M$56.5M−2.6%
Operating income and margin$5.27M · 9.6%$7.59M · 13.4%−31%, margin −3.8 pts
Net income$5.96M$8.19M−27%
Operating cash flow$14.58M$1.62M+798%
Cash$41.55M$36.54M+14%
New legal mentions (2)
  • AstraZeneca's request for certain reimbursable costs related to the district court litigation, some of which are opposed, remains pending.
  • An intention to grant was issued in connection with EP 23157078.9 on September 22, 2026.

Data on this page was fetched . The filing on SEC.gov is the record.